A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Phase 1 Completed 30 enrolled Insmed Incorporated

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of the study is to compare the PK of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.

Timeline

Start: 2022-10-04
Primary completion: 2023-06-01
Completion: 2023-06-01

Publications

Usansky H, Au Yeung S, Li S, Marbury T, Lawitz E, Kayali Z, Stein DS. Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions. Clin Pharmacokinet. 2026 Mar;65(3):441-452. doi: 10.1007/s40262-025-01614-0. Epub 2026 Jan 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brensocatib	Small molecule	25 mg	Oral

Indications

No indication recorded.